Definitive Contract 75N91019C00031

This is a $1,484,350.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Shuttle Pharmaceuticals, Inc., a small business Subchapter S Corporation. The contract is for cell-based models for prostate cancer health disparity research as part of the Cancer Moonshot program (Phase II). The contract has a total small business set aside designation and an ultimate completion date of November 16, 2021. This award builds upon a previous contract with...

<p>The U.S. National Cancer Institute awarded a $299,502 Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a small business located in Gaithersburg, Maryland. The contract is for the development of &quot;Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation Late Effects.&quot; This is a Firm Fixed Price definitive contract with a period of performance through September 18, 2017.</p>

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

This $17,053.58 firm fixed price purchase order was awarded by the National Cancer Institute (NCI), a civilian agency, to an undisclosed prime contractor on September 11, 2024. The contract is for a service agreement with a period of performance through March 10, 2025. No set-aside designation is indicated. The contract award does not provide details about the specific products or services to be delivered, but as the NCI is the funding agency, the work is likely related to the institute's cancer...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging &amp; Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of &quot;Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning&quot; as described in the original solicitation. This Phase I SBIR contract has a period of performance from...

<p>This is a $2,300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Cancer Targeted Technology LLC, a small business located in Pullman, Washington. The contract is for the development of an innovative Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy for prostate cancer. The contract has a completion date of August 29, 2018. This award represents a set-aside for small businesses.</p>

This is a firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Digital Artefacts LLC, a minority-owned, small disadvantaged business. The contract is for the development of a &quot;CANCER PATIENT COGNITIVE ASSESSMENT PLATFORM&quot; under TOPIC 343, with a ceiling value of $216,431.00 and a completion date of September 18, 2017. The contract does not have a set-aside designation. As the NCI is the funding agency, this contract supports the...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Pieces Technologies Inc., a small business, under the Small Business Innovation Research (SBIR) Phase II program. The contract, worth $1,999,994.00, is for the project titled &quot;Passive and Active AI Screening for Social Determinants of Health and Interventions to Improve Outcomes in the Cancer Patient Population.&quot; The contract has a period of performance from September 16,...